Fairvalue-Calculator Fairvalue-Calculator
EN DE

Reckitt Benckiser Group (RBGLY) Fair Value & Analysis

Consumer Defensive · US · Market cap $39.5B

Price$12.41
Fair Value$17.31
Upside+39.5%
Quality95/100
Evidence: High Range $10.94 – $29.03

Analysis

Reckitt Benckiser Group (RBGLY) currently trades at $12.41, while our model-based Fair Value estimate is $17.31 — implying the stock looks roughly 39.5% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.

Open the full interactive analysis →

Similar stocks

The Procter & Gamble Company (PG) -33% L'Oréal S.A (LRLCF) -54% Unilever PLC (UNLYF) -22% Colgate-Palmolive Company (CPA) -30% Hindustan Unilever Limited (HINDUNILVR) -54% Henkel AG (HENOY) +2%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.